These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33115981)

  • 1.
    Lee YS; Lee JY; Song SH; Kim DM; Lee JW; Chi XZ; Ito Y; Bae SC
    Mol Cells; 2020 Oct; 43(10):889-897. PubMed ID: 33115981
    [No Abstract]   [Full Text] [Related]  

  • 2. Runx3 Restoration Regresses K-Ras-Activated Mouse Lung Cancers and Inhibits Recurrence.
    Lee JY; Lee JW; Park TG; Han SH; Yoo SY; Jung KM; Kim DM; Lee OJ; Kim D; Chi XZ; Kim EG; Lee YS; Bae SC
    Cells; 2023 Oct; 12(20):. PubMed ID: 37887282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma.
    Lee YS; Lee JW; Jang JW; Chi XZ; Kim JH; Li YH; Kim MK; Kim DM; Choi BS; Kim EG; Chung JH; Lee OJ; Lee YM; Suh JW; Chuang LS; Ito Y; Bae SC
    Cancer Cell; 2013 Nov; 24(5):603-16. PubMed ID: 24229708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of RUNX3 in Restriction Point Regulation.
    Lee JW; Lee YS; Kim MK; Chi XZ; Kim D; Bae SC
    Cells; 2023 Feb; 12(5):. PubMed ID: 36899846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer.
    Lee KS; Lee YS; Lee JM; Ito K; Cinghu S; Kim JH; Jang JW; Li YH; Goh YM; Chi XZ; Wee H; Lee HW; Hosoya A; Chung JH; Jang JJ; Kundu JK; Surh YJ; Kim WJ; Ito Y; Jung HS; Bae SC
    Oncogene; 2010 Jun; 29(23):3349-61. PubMed ID: 20228843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination.
    Chi XZ; Kim J; Lee YH; Lee JW; Lee KS; Wee H; Kim WJ; Park WY; Oh BC; Stein GS; Ito Y; van Wijnen AJ; Bae SC
    Cancer Res; 2009 Oct; 69(20):8111-9. PubMed ID: 19808967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status.
    Omar MF; Ito K; Nga ME; Soo R; Peh BK; Ismail TM; Thakkar B; Soong R; Ito Y; Salto-Tellez M
    Pathol Oncol Res; 2012 Oct; 18(4):783-92. PubMed ID: 22729835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice.
    Duan W; Gao L; Kalvala A; Aguila B; Brooks C; Mo X; Ding H; Shilo K; Otterson GA; Villalona-Calero MA
    Int J Cancer; 2019 Nov; 145(9):2418-2426. PubMed ID: 30873587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How do K-RAS-activated cells evade cellular defense mechanisms?
    Lee YS; Bae SC
    Oncogene; 2016 Feb; 35(7):827-32. PubMed ID: 25961920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RUNX3 and p53: How Two Tumor Suppressors Cooperate Against Oncogenic Ras?
    Lee JW; van Wijnen A; Bae SC
    Adv Exp Med Biol; 2017; 962():321-332. PubMed ID: 28299666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
    Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
    Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence.
    Volonte D; Vyas AR; Chen C; Dacic S; Stabile LP; Kurland BF; Abberbock SR; Burns TF; Herman JG; Di YP; Galbiati F
    J Biol Chem; 2018 Feb; 293(5):1794-1809. PubMed ID: 29247004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53.
    Yamada C; Ozaki T; Ando K; Suenaga Y; Inoue K; Ito Y; Okoshi R; Kageyama H; Kimura H; Miyazaki M; Nakagawara A
    J Biol Chem; 2010 May; 285(22):16693-703. PubMed ID: 20353948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoform-Specific Effects of Wild-Type Ras Genes on Carcinogen-Induced Lung Tumorigenesis in Mice.
    Weyandt JD; Carney JM; Pavlisko EN; Xu M; Counter CM
    PLoS One; 2016; 11(12):e0167205. PubMed ID: 27911940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-301a promotes lung tumorigenesis by suppressing Runx3.
    Li X; Zhong M; Wang J; Wang L; Lin Z; Cao Z; Huang Z; Zhang F; Li Y; Liu M; Ma X
    Mol Cancer; 2019 May; 18(1):99. PubMed ID: 31122259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
    Esteban-Burgos L; Wang H; Nieto P; Zheng J; Blanco-Aparicio C; Varela C; Gómez-López G; Fernández-García F; Sanclemente M; Guerra C; Drosten M; Galán J; Caleiras E; Martínez-Torrecuadrada J; Fajas L; Peng SB; Santamaría D; Musteanu M; Barbacid M
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24415-24426. PubMed ID: 32913049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
    Kasinski AL; Slack FJ
    Cancer Res; 2012 Nov; 72(21):5576-87. PubMed ID: 22964582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
    Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
    Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deregulated lncRNA expression profile in the mouse lung adenocarcinomas with KRAS-G12D mutation and P53 knockout.
    Zhang M; Jiang N; Cui R; Du S; Ou H; Chen T; Ge R; Ma D; Zhang J
    J Cell Mol Med; 2019 Oct; 23(10):6978-6988. PubMed ID: 31410985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirt1 protects from K-Ras-driven lung carcinogenesis.
    Costa-Machado LF; Martín-Hernández R; Sanchez-Luengo MÁ; Hess K; Vales-Villamarin C; Barradas M; Lynch C; de la Nava D; Diaz-Ruiz A; de Cabo R; Cañamero M; Martinez L; Sanchez-Carbayo M; Herranz D; Serrano M; Fernandez-Marcos PJ
    EMBO Rep; 2018 Sep; 19(9):. PubMed ID: 30021836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.